Cancer
EmpowHER 303
Breast Cancer
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Contact Research Team:
[email protected]
Site principal investigator:
Timothy Pluard, MD
Learn more about this study:
NCT06435429